446880-83-7Relevant articles and documents
ALK5 INHIBITOR CONJUGATES AND USES THEREOF
-
Paragraph 0158; 0169-0170, (2021/07/17)
The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr
ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
-
Paragraph 0166; 0177-0178, (2020/06/07)
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling
Ciayadi, Rudy,Potdar, Mahesh,Walton, Kelly L.,Harrison, Craig A.,Kelso, Geoffrey F.,Harris, Simon J.,Hearn, Milton T.W.
supporting information; experimental part, p. 5642 - 5645 (2011/10/09)
Novel inhibitors of TGF-β1 and activin A signalling based on a 2-aryl-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine pharmacophore have been synthesised. Compounds containing phenyl or aromatic nitrogen heterocycle substituents inhibited both types of signalling with HEK-293T cells in culture, with a selectivity preference for TGF-β1. Synthetic compounds containing pyridin-3-yl, pyrazol-4-yl, pyrazol-1-yl or 1H-imidazoyl-1-yl substituents exhibited structural and functional attributes suitable for further investigation related to the development of more potent TGF-β inhibitors.